Comparing efficacy and side effects of Memantine and Risperidone in treating autistic patients
Phase 3
- Conditions
- Autism.Pervasive developmental disorders
- Registration Number
- IRCT201204037202N5
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
inclusion criteria: age of 4-17 year old; autistic patients not received any drug for treatment in past or not responded adequately to previous drugs; seizure attacks in epileptic patients should be controlled and any change in dose and kind of antiepileptic drugs should not be made from one month before entrance to the study.
exclusion criteria: any neurologic disease except for seizure; substance abuse; pregnancy; any history of neuroleptic malignant syndrom and history of allergic reactions to mementine or risperidone; history of cardiovascular diseases, malignant hematologic diseases, acute kidney or liver failure.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Autism symptoms. Timepoint: before intervention, four and eight weeks after intervention. Method of measurement: Aberrant Behavioral Check list and Childhood Autism Rating Scale scales.
- Secondary Outcome Measures
Name Time Method Side effects including any side effect that related to the drug. Timepoint: two, four and eight weeks after intervention. Method of measurement: side effects checklist.